Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
MoonLake Immunotherapeutics ( (MLTX) ) has shared an announcement.
On November 5, 2025, MoonLake Immunotherapeutics announced promising results from its Phase 2 clinical trial of Sonelokimab in palmoplantar pustulosis and an interim analysis of its Phase 3 trial in adolescents with hidradenitis suppurativa. The company also reported its third-quarter financial results, highlighting a cash position of $380.5 million, expected to fund operations into the second half of 2027. These developments underscore MoonLake’s strategic progress in advancing Sonelokimab’s clinical program, potentially enhancing its market position in the inflammatory disease sector.
The most recent analyst rating on (MLTX) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on MoonLake Immunotherapeutics stock, see the MLTX Stock Forecast page.
Spark’s Take on MLTX Stock
According to Spark, TipRanks’ AI Analyst, MLTX is a Neutral.
MoonLake Immunotherapeutics presents a high-risk, high-reward scenario typical for early-stage biotech firms. The strong balance sheet and recent financing provide a solid financial foundation, but the lack of revenue and operational losses weigh heavily on the score. Technical indicators are mixed, and the negative valuation metrics reflect the developmental nature of the company. The significant financing event is a positive catalyst, enhancing the company’s ability to advance its pipeline.
To see Spark’s full report on MLTX stock, click here.
More about MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for inflammatory diseases. The company is leveraging its novel investigational Nanobody®, Sonelokimab, to address major unmet needs in conditions such as hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and palmoplantar pustulosis.
Average Trading Volume: 4,475,513
Technical Sentiment Signal: Sell
Current Market Cap: $650.7M
For an in-depth examination of MLTX stock, go to TipRanks’ Overview page.